Stryker (NYSE:SYK) Shares Gap Up on Strong Earnings

Stryker Corporation (NYSE:SYK)’s share price gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $354.30, but opened at $369.10. Stryker shares last traded at $368.9750, with a volume of 371,383 shares changing hands.

The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period last year, the company posted $4.01 EPS.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. This is a positive change from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s dividend payout ratio is presently 46.25%.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Q4 results beat expectations — Adjusted EPS of $4.47 vs. $4.40 consensus and revenue $7.17B (organic sales +11%). Management also reported expanded adjusted operating margin (30.2% in Q4). This confirms healthy demand across MedSurg/Neuro and Orthopaedics and supports upside to earnings momentum. GlobeNewswire — Stryker reports 2025 operating results and 2026 outlook
• Positive Sentiment: Company raised full?year outlook — Stryker expects 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS $14.90–$15.10, citing procedural volume and capital demand; management signaled continued margin expansion. This underpins forward earnings visibility and supports valuation. Reuters — Stryker raises annual profit forecast
• Positive Sentiment: Analyst uplift — Needham raised its SYK price target to $454 and reiterated a Buy (now ~28% upside from the cited price) and other firms (Piper Sandler, BTIG, etc.) remain constructive, which can boost sentiment/flows into the stock. Benzinga — Needham raises price target
• Neutral Sentiment: FY?2026 EPS guidance roughly in line with consensus — The $14.90–15.10 range is close to the Street estimate (~$14.96). Guidance reduces uncertainty but leaves limited surprise risk unless execution deviates. Seeking Alpha — Stryker projects 8%–9.5% organic sales growth for 2026
• Neutral Sentiment: Analyst commentary acknowledges risks but keeps Buy ratings — Needham and others emphasize sustained double?digit growth and operating leverage even as they note external headwinds. That keeps consensus constructive but watches remain on execution. TipRanks — analyst revisit / Needham
• Negative Sentiment: Tariff and macro/legal/regulatory risks flagged — Analysts and the company call out potential tariff headwinds, regulatory and recall-related risks, and FX/market volatility that could pressure margins or growth if realized. These are watch items that could trim upside. Reuters — risk commentary
• Negative Sentiment: Insider selling and historic impairments — Recent data cited by market sites note notable insider sales activity and past goodwill/asset impairments (reminder to monitor governance and one?off charges that can affect reported earnings). QuiverQuant summary — insider activity & impairments

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent research reports. Royal Bank Of Canada restated an “outperform” rating and set a $435.00 target price on shares of Stryker in a report on Friday, November 14th. Piper Sandler restated an “overweight” rating on shares of Stryker in a research note on Tuesday. UBS Group set a $408.00 target price on Stryker in a research note on Monday, October 13th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Finally, Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a report on Tuesday, January 6th. Twelve research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $426.95.

Insider Transactions at Stryker

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stryker

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Torren Management LLC bought a new stake in shares of Stryker during the 4th quarter worth about $86,000. Rogco LP lifted its holdings in shares of Stryker by 9.2% in the fourth quarter. Rogco LP now owns 1,517 shares of the medical technology company’s stock valued at $533,000 after buying an additional 128 shares during the period. Ares Financial Consulting LLC acquired a new stake in Stryker in the 4th quarter valued at about $40,000. R Squared Ltd lifted its stake in Stryker by 7.1% during the fourth quarter. R Squared Ltd now owns 4,314 shares of the medical technology company’s stock valued at $1,516,000 after purchasing an additional 286 shares during the last quarter. Finally, M&T Bank Corp increased its holdings in shares of Stryker by 10.0% in the fourth quarter. M&T Bank Corp now owns 47,160 shares of the medical technology company’s stock valued at $16,575,000 after buying an additional 4,287 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Up 3.9%

The firm has a market capitalization of $140.78 billion, a P/E ratio of 48.44, a price-to-earnings-growth ratio of 2.29 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. The firm has a 50 day moving average price of $359.38 and a two-hundred day moving average price of $371.95.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.